Preclinical assessment of a zwitterionic tantalum oxide nanoparticle X-ray contrast agent

ACS Nano. 2012 Aug 28;6(8):6650-8. doi: 10.1021/nn300928g. Epub 2012 Jul 25.

Abstract

Tantalum oxide nanoparticles show great potential as the next generation of X-ray contrast media. Recently, we reported advances in tantalum oxide nanoparticles and identified improvements that were required for such particles to progress further. Namely, the viscosity of concentrated particles, the amount of retention in reticuloendothelial (RES) tissues, and the effect of large quantities of particles on the kidneys after administration were all identified as critical factors which needed further study, understanding, and development. Here, we report on a zwitterionic siloxane polymer nanoparticle coating that reduced the viscosity of concentrated solutions of particles by a factor of 5, decreased tissue retention of injected particles by a factor of 10, and, importantly, did not induce pathological responses in the kidneys.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Contrast Media / adverse effects
  • Contrast Media / chemical synthesis
  • Kidney / drug effects
  • Materials Testing
  • Metabolic Clearance Rate
  • Nanocapsules / adverse effects
  • Nanocapsules / chemistry*
  • Organ Specificity
  • Oxides / adverse effects
  • Oxides / pharmacokinetics*
  • Particle Size
  • Rats
  • Siloxanes / chemistry*
  • Tantalum / adverse effects
  • Tantalum / pharmacokinetics*
  • Tissue Distribution
  • Tomography, X-Ray Computed / methods*

Substances

  • Contrast Media
  • Nanocapsules
  • Oxides
  • Siloxanes
  • Tantalum
  • tantalum oxide